Lipvas 20mg is a pharmaceutical product representing the advancements in contemporary medicine, specifically designed to manage lipid disorders and promote cardiovascular health. It contains Atorvastatin, a potent statin medication known for its cholesterol-lowering properties.
Heart & Blood Pressure
Lipvas (Atorvastatin) 20 Mg Tablet
$1.03
Generic For Lipitor
Generic Name Atorvastatin
Ingredients
Each Lipvas 20mg tablet contains Atorvastatin as its active ingredient. Atorvastatin works by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in cholesterol synthesis in the liver. By reducing cholesterol production, Lipvas helps lower total cholesterol, LDL (low-density lipoprotein) or “bad” cholesterol, and triglycerides, while simultaneously increasing HDL (high-density lipoprotein) or “good” cholesterol levels.
Product
Lipvas 20mg contributes to the management of lipid disorders, particularly hypercholesterolemia. By regulating cholesterol levels, it helps prevent the buildup of plaque in the arteries, reducing the risk of atherosclerosis and cardiovascular events. Lipvas is an integral part of a comprehensive approach to cardiovascular health.
Usage
Patients are advised to follow the prescribed guidelines for Lipvas 20mg. The tablets are meant for oral consumption and should be taken as directed by healthcare professionals. It is essential to adhere to a healthy lifestyle, including a balanced diet and regular exercise, to enhance the effectiveness of Lipvas in managing lipid levels.
Manufacturer
Lipvas 20mg is manufactured by Cipla adhering to high-quality standards. It is crucial to obtain this medication from reputable sources to ensure its efficacy and safety.
In summary, Lipvas 20mg offers an effective solution for individuals dealing with lipid disorders, providing a reliable means to regulate cholesterol levels and promote cardiovascular health. Always consult with your healthcare provider for personalized advice and recommendations regarding the use of Lipvas 20mg.
Reviews
There are no reviews yet.